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Review Article
Scissor sisters: regulation of ADAM10 by the
TspanC8 tetraspanins
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Correspondence: Michael G. Tomlinson (m.g.tomlinson@bham.ac.uk)
A disintegrin and metalloprotease 10 (ADAM10) is a ubiquitously expressed transmem-
brane protein which is essential for embryonic development through activation of Notch
proteins. ADAM10 regulates over 40 other transmembrane proteins and acts as a
‘molecular scissor’ by removing their extracellular regions. ADAM10 is also a receptor for
α-toxin, a major virulence factor of Staphylococcus aureus. Owing to the importance of
its substrates, ADAM10 is a potential therapeutic target for cancer, neurodegenerative
diseases such as Alzheimer’s and prion diseases, bacterial infection and inﬂammatory
diseases such as heart attack, stroke and asthma. However, targetting ADAM10 is likely
to result in toxic side effects. The tetraspanins are a superfamily of 33 four-transmem-
brane proteins in mammals which interact with and regulate speciﬁc partner proteins
within membrane nanodomains. Tetraspanins appear to have a cone-shaped structure
with a cholesterol-binding cavity, which may enable tetraspanins to undergo cholesterol-
regulated conformational change. An emerging paradigm for tetraspanin function is the
regulation of ADAM10 by the TspanC8 subgroup of tetraspanins, namely Tspan5, 10, 14,
15, 17 and 33. This review will describe how TspanC8s are required for ADAM10 trafﬁck-
ing from the endoplasmic reticulum and its enzymatic maturation. Moreover, different
TspanC8s localise ADAM10 to different subcellular localisations and may cause ADAM10
to adopt distinct conformations and cleavage of distinct substrates. We propose that
ADAM10 should now be regarded as six different scissor proteins depending on the
interacting TspanC8. Therapeutic targetting of speciﬁc TspanC8/ADAM10 complexes
could allow ADAM10 targetting in a cell type- or substrate-speciﬁc manner, to treat
certain diseases while minimising toxicity.
Introduction
Cell development and function are regulated by cell surface receptors and secreted proteins that
co-ordinate intra- and intercellular signalling. Various regulatory mechanisms are required to ensure
appropriate spatiotemporal control over these biological processes. Proteolytic cleavage, or ‘shedding’, of
the ectodomains (extracellular regions) at a juxta-membrane site on transmembrane proteins has
emerged as one such mechanism. Ectodomain shedding directly affects the responsiveness of cells to
extracellular signals via activation of intracellular signalling or down-regulation of cell surface receptors,
or indirectly through the release of soluble mediators from their membrane-bound precursors. Shedding
therefore enables cells to rapidly respond to their environment and plays an important role in copious cel-
lular processes including cell adhesion, migration, invasion, proliferation and signalling [1,2].
ADAM10: a ubiquitous ‘molecular scissor’
The evolutionarily conserved ADAMs (a disintegrin and metalloproteases) are a superfamily of Zn2+-
dependent transmembrane metalloproteases that are responsible for a substantial proportion of
transmembrane protein shedding. A total of 22 ADAM genes have been identiﬁed in humans, of
which 12 encode proteolytically active enzymes. ADAMs share a common multidomain structure
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consisting of an N-terminal signal sequence, followed by a prodomain, a metalloprotease domain, a disintegrin
domain, a cysteine-rich region, an epidermal growth factor (EGF) domain (except ADAM10 and ADAM17), a
transmembrane region and a cytoplasmic tail (Figure 1) [3]. Metalloproteases are synthesised as zymogens and
undergo maturation during biosynthesis. This is the process by which the prodomain, which acts as a chaper-
one and an inhibitor of enzyme activity, is cleaved by proprotein convertases [4].
ADAM10 is ubiquitously expressed in mammalian cells and is one of the best studied ADAMs with over 40
substrates identiﬁed [5,6]. ADAM10 is essential for embryonic development, because ADAM10-deﬁcient mice die
at embryonic day 9.5 and display a defective neuronal and vascular phenotype [7]. This is comparable with fea-
tures observed in mice deﬁcient for the cell fate regulator Notch1. Indeed, ADAM10 is responsible for the ligand-
dependent cleavage of Notch proteins, which enables the membrane-tethered fragment of Notch to undergo
intramembrane proteolysis within its transmembrane region by γ-secretase. This results in the translocation of the
Notch intracellular domain to the nucleus where it functions as a transcriptional regulator [8–11].
A second well-studied ADAM10 substrate is the amyloid precursor protein (APP). Cleavage of the APP by
β- and γ-secretases generates the pathogenic amyloid peptide Aβ, which forms amyloid plaques and has been
associated with Alzheimer’s disease. ADAM10 can prevent the formation of the Aβ peptide in a mouse model by
cleaving APP at a site within the Aβ peptide region [12]. Thus, induction of ADAM10 activity has therapeutic
potential for the treatment of Alzheimer’s disease. Similarly, ADAM10 activation has been proposed as a potential
treatment for prion disease, because ADAM10 sheds the cellular prion protein and conditional deletion of
ADAM10 in forebrain neurones reduces survival time in a mouse model of prion disease [13]. However, the role
of ADAM10 in prion disease is complicated, because ADAM10 also reduces spread of the disease throughout the
brain and reduces neuropathological consequences [13]. Induction of ADAM10 activity is also a potential treat-
ment for arterial thrombosis, which leads to heart attack and ischaemic stroke. ADAM10 sheds the
platelet-activating collagen receptor glycoprotein VI (GPVI) [14,15], and GPVI deﬁciency protects against arterial
thrombosis in mouse models [16]. In contrast with these therapeutic possibilities to activate ADAM10, inhibition
of ADAM10 has potential for the treatment of other diseases. ADAM10 may promote cancer progression by
shedding and release of EGF receptor ligands betacellulin and EGF [17], for example, and may promote asthma
by cleaving the low-afﬁnity immunoglobulin E receptor CD23 [18,19]. ADAM10 may also promote inﬂammatory
diseases by releasing chemokines CX3CL1 and CXCL16 [20], and by weakening epithelial and endothelial cell–
cell junctions by cleaving epithelial (E), neuronal (N) and vascular endothelial (VE) cadherins [21–23]. In add-
ition, ADAM10 is a receptor for Staphylococcus aureus α-toxin, which activates ADAM10 to cleave cadherins on
epithelial and endothelial cells. This disrupts barrier formation to promote tissue damage and spread of the bac-
teria [24]. Thus, ADAM10 has a wide range of substrates with important roles in health and disease, and
ADAM10 shedding can be disease-preventing or disease-promoting, depending on the substrate.
Figure 1. Diagrammatic representation of ADAM10 cleaving a substrate.
N-glycosylation sites are indicated by ﬁlled ovals.
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The regulation of ADAM10 activity is not clear. ADAM10 appears to have constitutive activity towards
some substrates, although its activity can be up-regulated by certain stimuli that induce intracellular signals,
such as an increase in intracellular Ca2+ concentration. The mechanism underlying the latter is not well under-
stood, but is dependent on the transmembrane region of ADAM10 rather than the cytoplasmic tail [25]. There
is also evidence that ADAM10-mediated shedding may be facilitated by intracellular signals that modify the
substrates, because phosphorylation of the cytoplasmic tail of the adhesion molecule CD44 may induce dimer-
isation and/or a conformational change in the CD44 ectodomain to allow shedding [26,27].
ADAM10 is clearly a promising therapeutic target for a range of diseases, but because of the positive and
negative effects of ADAM10 in health and disease processes, substrate-speciﬁc ADAM10 targetting may be
necessary to avoid toxic side effects. The remainder of this review will describe the emerging role of the
TspanC8 tetraspanins as ADAM10-interacting partners that are essential for its exit from the endoplasmic
reticulum, and which may dictate substrate speciﬁcity.
Tetraspanins regulate partner protein function
The regulation of transmembrane proteins by compartmentalisation into membrane microdomains is a concept
that has developed from studies of lipid rafts, caveolae, neuronal and immunological synapses, and tetraspanins.
The latter are a superfamily of four-transmembrane proteins that are expressed by animals, plants and some
multicellular fungi. They function by interacting with speciﬁc ‘partner proteins’, and regulating their intracellu-
lar trafﬁcking and lateral mobility and clustering at the cell surface [28,29]. Notable examples are regulation of
laminin-binding integrin function by tetraspanin CD151 [29], regulation of B-cell co-receptor CD19 trafﬁcking
by tetraspanin CD81 [30] and regulation of the Wnt receptor Frizzled-4 by Tspan12 [31]. In each case, tetra-
spanin mutations lead to human diseases that are consistent with functional impairment of the partner protein:
CD151 deﬁciency leads to kidney disease due to impaired assembly of the glomerular and tubular basement
membranes [32]; CD81 deﬁciency leads to impaired antibody generation due to an absence of CD19 on the
B-cell surface [33]; and Tspan12 deﬁciency leads to familial exudative vitreoretinopathy characterised by
impaired vasculature development in the retina [34,35]. A total of 33 tetraspanins are found in humans and
each cell type is estimated to express as many as 20 different tetraspanins. Tetraspanins form dynamic
nanoclusters that are distinct from lipid rafts [28,29], and recent evidence using super-resolution microscopy
suggests that tetraspanin nanodomains are clusters of ∼10 tetraspanins of just a single type [36]. This is con-
sistent with the speciﬁc phenotypes that have been observed in many tetraspanin knockout studies, although
tetraspanin knockouts are typically well tolerated and there is evidence for functional compensation by related
tetraspanins [28,29].
An exciting breakthrough in tetraspanin research is the recent report of the ﬁrst crystal structure of a full-
length tetraspanin [37]. The Blacklow group showed that tetraspanin CD81 has a cone-like structure in which
Figure 2. Diagrammatic representation of a tetraspanin in closed and open conformations.
The variable region of the major extracellular region is indicated in blue. Tetraspanins have between 0 and 3 N-linked
glycosylation sites and several cysteine residues which can be palmitoylated (indicated in blue). This model is based on the
crystal structure of tetraspanin CD81 [37]; additional structures are required to determine whether this is a common structure
for all tetraspanins.
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transmembranes 1 and 2 are separated at the top of the plasma membrane from transmembranes 3 and 4
(Figure 2A). This forms a cavity in which a cholesterol molecule can bind, with its hydroxyl group co-ordinated
by conserved polar amino acids within transmembranes 1 and 4. Molecular dynamics simulations suggest that
removal of the cholesterol might result in a dramatic conformational change from a ‘closed’ to an ‘open’ con-
formation, in which the main extracellular region swings upwards with a ‘switch-blade’-type action (Figure 2B)
[37]. Structural determination of additional tetraspanins is now required to discover whether this structure is
common to the entire superfamily. Nevertheless, this raises the possibility of therapeutic targetting with small
molecules or antibodies that may lock the tetraspanin into a particular conformation. Hypothetically, this could
then affect partner protein function, for example, by disrupting the interaction with the tetraspanin, by affecting
localisation of the complex (e.g. causing internalisation) or by preventing conformational change-induced regu-
lation by the tetraspanin.
The emergence of the six TspanC8 tetraspanins as
ADAM10 regulators
ADAM10 is one of the most commonly identiﬁed tetraspanin-associated proteins in proteomic studies, and the
majority of ADAM10 appears to be tetraspanin-associated [38]. In 2012, we and others reported this to be
mediated by an interaction with any one of six largely unstudied tetraspanins that are particularly related by
protein sequence [39–41]. These are Tspan5, 10, 14, 15, 17 and 33, which we termed the TspanC8 subgroup
because they are unique among tetraspanins in possessing eight cysteines within their main extracellular region
[39,40]. TspanC8s promote ADAM10 exit from the endoplasmic reticulum and removal of its inhibitory pro-
domain, and most TspanC8s promote trafﬁcking to the cell surface (Figure 3) [39–41]. This mechanism holds
true in Drosophila [39], primary human endothelial cells [40] and in red blood cells through our study of
Figure 3. The six TspanC8s regulate ADAM10 trafﬁcking and maturation.
TspanC8s interact with ADAM10 and promote its trafﬁcking out of the endoplasmic reticulum and its maturation, during which
the inhibitory prodomain is cleaved. TspanC8s may trafﬁc ADAM10 to the cell surface or to intracellular compartments
(e.g. Tspan10 appears to be largely intracellular). TspanC8s promote ADAM10 speciﬁcity for certain substrates (e.g. Tspan15
promotes N-cadherin cleavage).
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Tspan33 knockout mice [40], so far the only reported TspanC8 knockout mouse [42], together indicating that
TspanC8s are fundamental to ADAM10 function.
Several follow-up studies on TspanC8 regulation of ADAM10 [43–46] can be condensed into the following
key ﬁndings: (1) different cell types have distinct repertoires of TspanC8 expression; (2) different TspanC8s
have distinct subcellular localisations and lateral diffusion; (3) different TspanC8s interact with distinct regions
of the ADAM10 extracellular region, suggesting that ADAM10 adopts different conformations in complex with
different TspanC8s and (4) different TspanC8s can promote, or inhibit, ADAM10 cleavage of distinct sub-
strates. These ﬁndings, which will be expanded on in the rest of this review, have led us to propose that
ADAM10 can no longer be regarded as one molecular scissor. Instead, ADAM10 exists as six different scissors
with different substrate speciﬁcities, depending on which TspanC8 it is associated with (Figure 4) [44].
It is worth noting that prior to the studies on TspanC8s, the non-TspanC8 tetraspanin Tspan12 was impli-
cated in ADAM10 regulation [47]. However, this is now thought to be an indirect effect, because unlike
TspanC8s, no Tspan12 co-immunoprecipitation with ADAM10 is detected under stringent lysis conditions
[39,40]. More recently, Tspan3 has been shown to interact with ADAM10 and APP [48]. Tspan3 is not a
TspanC8, but forms a subgroup of inter-related tetraspanins that include Tspan6 and 7. Unlike TspanC8s,
Tspan3 overexpression does not promote ADAM10 maturation or trafﬁcking to the cell surface, but does
promote APP cleavage. No effects on APP cleavage are detectable in brains of Tspan3 knockout mice, but this
could be due to compensation by the related Tspan7, which is up-regulated at the mRNA level in the absence
of Tspan3 [48]. Additional studies are needed to determine how ADAM10 is regulated by Tspan3, and possibly
by Tspan6 and 7, and their potential interplay with TspanC8s.
Different cell types have distinct TspanC8 repertoires
In the absence of effective antibodies to most TspanC8s, we have used RT-PCR to determine mRNA expression
levels of TspanC8s in different cell types. Primary human umbilical vein endothelial cells and the A549 lung
epithelial cell line express most of the TspanC8s, but primary mouse erythroblasts and megakaryocytes express
predominantly one TspanC8, namely Tspan33 and Tspan14, respectively. Analyses of an additional eight
human cell lines suggest that expression of most of the six TspanC8s is a common feature, albeit with consider-
able variation in relative levels between cell types (Figure 5A). Similarly, examination of TspanC8 expression
within an RNA-Seq dataset, from seven major cell types in mouse brain [49], indicates that most cell types
express most TspanC8s, but at levels speciﬁc to the cell type (Figure 5B). Oligodendrocyte precursors express
ﬁve TspanC8s, with highest expression of Tspan5 and Tspan14. This pattern is similar in astrocytes and neu-
rones, but in myelinating oligodendrocytes Tspan15 is the most highly expressed and Tspan33 is lost. The
macrophages of the brain, the microglia, express Tspan14 and Tspan33, while brain endothelial cells express
Tspan5, 14, 15 and 17 (Figure 5B) [49], similar to human umbilical vein endothelial cells [40]. Given that
ADAM10 has several substrates in the brain, including APP and cellular prion protein [6], it will be of interest
to investigate brain function in TspanC8 knockout mice as they become available. Taken together, it is clear
that different cell types have different repertoires of ADAM10 scissors, providing ample scope for differential
Figure 4. Diagrammatic representation of the six different TspanC8/ADAM10 complexes.
The different conformations of ADAM10 in complex with different TspanC8s are hypothetical, but are based on interaction mapping data by Noy
et al. [45]. N-glycosylation sites are indicated by ﬁlled ovals, but palmitoylation sites are not shown.
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Figure 5. Different cell types express distinct repertoires of TspanC8s.
(A) The mRNA levels of TspanC8s in different human cell lines were measured by quantitative real-time polymerase chain
reaction, as previously described [40]. The cell lines were human embryonic kidney 293 cells expressing the large T antigen of
SV40 virus (HEK-293T), HeLa epithelial cells, DU145 prostate cancer cells, Jurkat T cells, K562 chronic myelogenous
leukaemia cells, human erythroleukaemia cells (HEL) and DAMI megakaryoblast cells. (B) An RNA-Seq dataset from mouse
brain for seven major cell types, generated by Zhang et al. [49], was used to present mRNA expression levels for TspanC8s as
fragments per kilobase of transcript sequence per million mapped fragments (FPKM).
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substrate shedding and the potential for therapeutic targetting in a cell type- or substrate-speciﬁc manner by
targetting speciﬁc TspanC8/ADAM10 complexes.
Different TspanC8s have distinct subcellular localisations
and lateral diffusion
The Rubinstein group have investigated TspanC8 subcellular localisation by transfecting green ﬂuorescent
protein (GFP)-tagged TspanC8s into human cell lines. Tspan5, 14, 15 and 33 promote ADAM10 surface local-
isation in the HeLa epithelial cell line, but Tspan10 and 17 do not. This is consistent with substantial localisa-
tion of the latter in an intracellular compartment, but cell surface and intracellular localisation of the other four
TspanC8s [39]. In subsequent comparisons between GFP-tagged Tspan5 and 15 expressed in the U2OS osteo-
sarcoma cell line, ADAM10 lateral diffusion in the plasma membrane is increased by 55% in the presence of
Tspan15, but Tspan5 has no effect [43]. In addition, co-immunoprecipitation followed by mass spectrometry-
based proteomics identiﬁes many common interacting proteins, most prominently ADAM10, but some pro-
teins are more speciﬁc to Tspan5 or Tspan15. Additionally, overexpression of Tspan5 or Tspan15 appears to
alter the proteins interacting with ADAM10 [43]. These data suggest that TspanC8s differentially regulate
ADAM10 localisation, but interpretation is complicated by the fact that the GFP tag and/or overexpression
might affect localisation. TspanC8 monoclonal antibodies are now required to investigate the localisation of
endogenous proteins.
Different TspanC8s may cause ADAM10 to adopt distinct
conformations
We have demonstrated that the main extracellular region of Tspan14 mediates the interaction with ADAM10
and its maturation, and that the variable region is necessary but not sufﬁcient [45]. This study used
co-immunoprecipitation of overexpressed FLAG epitope-tagged constructs chimeric for Tspan14 and the
non-TspanC8 tetraspanin CD9. A similar strategy with ADAM10 truncation constructs and chimeras with
ADAM17, which does not interact with TspanC8s, showed some interesting differences between TspanC8s.
Tspan15 requires only the membrane–proximal stalk region of ADAM10 for its interaction, Tspan17 requires
the stalk and cysteine-rich domain, whereas Tspan5, 10, 14 and 33 require the stalk, cysteine-rich and disinte-
grin domains [45]. These ﬁndings suggest that ADAM10 might adopt different conformations in complex with
different TspanC8s, as suggested in Figure 4. However, interpretation of these data is complicated by their reli-
ance on co-immunoprecipitation of overexpressed mutant constructs, and thus, high-resolution structural
studies of native TspanC8/ADAM10 complexes are now required.
The cleavage sites on ADAM10 substrates share no particular amino acid sequence similarities and differ in
their position relative to the plasma membrane. For example, the GPVI, APP and Notch1 cleavage sites are
positioned at 5, 12 and 15 amino acids from the transmembranes, respectively [11,15,50]. Therefore, if different
TspanC8s are able to ‘lock’ ADAM10 into a distinct conformation, this could position the ADAM10 metallo-
protease domain at a position that favours cleavage of certain substrates.
Different TspanC8/ADAM10 complexes cleave distinct
substrates
The most deﬁnitive evidence for cleavage of speciﬁc ADAM10 substrates by different TspanC8/ADAM10 com-
plexes is the promotion of N-cadherin cleavage by Tspan15/ADAM10. This is because the experiments have
compared Tspan15 with other TspanC8s as controls have been reported by three different groups using differ-
ent cell lines and the effects are striking. Indeed, Tspan15 overexpression substantially promotes N-cadherin
cleavage, but other TspanC8s do not [41,43,45]. Furthermore, Tspan15 knockdown substantially reduces
N-cadherin cleavage [43].
Notch cleavage is also regulated by TspanC8s [39,43,46,51], but interpretation of these ﬁndings is compli-
cated by the positive and negative effects described for different TspanC8s, the different cell types used and the
different methods of activating Notch and detecting its cleavage. In the two studies which have compared dif-
ferent TspanC8s, ligand-induced Notch reporter activity in HeLa and U2OS cells is shown to be promoted by
overexpression of Tspan5 or 14, whereas Tspan15 or 33 has the opposite effect. Moreover, Tspan15 knockdown
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can substantially promote Notch activation [39,43]. In additional studies which focused on just one or two
TspanC8s, it was reported that knockdown of Tspan5 or 10 in primary mouse osteoclasts inhibits Notch cleav-
age and target gene expression [46], whereas Tspan33 has a positive role in expression of Notch target genes in
the RAW 264.7 mouse macrophage cell line [51]. Thus, Tspan5, 10 and 14 appear to be Notch-promoting,
Tspan15 Notch-inhibiting and Tspan33-dependent on the cell type. A panel of CRISPR/Cas9-generated cell
lines, expressing single TspanC8s, may ultimately be required to understand the importance of each TspanC8
in the activation of Notch and potentially other ADAM10 substrates.
Recent additional ﬁndings from cell line models suggest that GPVI, CD44 and APP cleavage may also be
regulated by speciﬁc TspanC8s. GPVI cleavage is inhibited by overexpression of Tspan14 but not by other
TspanC8s [45], and CD44 cleavage is partially dependent on Tspan5 but not on Tspan15 [43]. Finally, regula-
tion of APP cleavage by TspanC8s is less clear, because both positive [41] and negative [43] effects of Tspan15
have been reported. This may reﬂect the different cell lines used and their potentially different endogenous
TspanC8 repertoires.
Finally, genetic screens in cell lines have recently shown Tspan14 and Tspan33 to be important for cytotox-
icity induced by S. aureus α-toxin; the screens also identiﬁed the α-toxin receptor ADAM10 [52,53]. One
explanation for their identiﬁcation would be that these TspanC8s are highly expressed in the cell lines screened
and are required for ADAM10 surface expression, which certainly appears to be the case for Tspan14 in the
U937 human monocyte cell line [53]. However, it is possible that TspanC8s might differentially regulate
ADAM10 function as an α-toxin receptor.
The mechanisms by which TspanC8s differentially control ADAM10 substrate speciﬁcity are unclear, but the
regulation of ADAM10 subcellular localisation and conformation, proposed in the previous sections, represent
potential mechanisms. An additional possibility is direct interaction of the TspanC8 with a particular substrate.
However, although at least two ADAM10 substrates are tetraspanin-associated, namely CD44 [54] and GPVI
[55,56], there is no current evidence that a TspanC8 can interact with these proteins.
TspanC8 protein sequence analyses: conserved
transmembrane and extracellular regions; divergent tails
In the current absence of useful tools such as TspanC8 monoclonal antibodies and knockout mice (apart from
Tspan33 [40,42]), comparisons of TspanC8 protein sequences may help us to understand how they differen-
tially regulate ADAM10. TspanC8s are certainly relatively highly related by amino acid sequence [40], with the
human homologues ranging from 78% amino acid identity between Tspan5 and 17 to 26% identity between
the most distantly related TspanC8s, as determined by Clustal Omega multiple sequence alignment [57]
(Table 1). The large extracellular region is relatively highly conserved between TspanC8s (average 44% sequence
identity), with the ‘variable’ region even more conserved (59%) (Figure 6). This contrasts strikingly with
sequence comparisons within the tetraspanins as a whole, in which the variable region varies most between tet-
raspanins. However, this is consistent with our ﬁnding that the interaction with ADAM10 is mediated by the
main extracellular region of the TspanC8s and that the variable region is essential [45], suggesting that this
ADAM10-interacting region has been conserved during evolution. The transmembrane domains of TspanC8s
are also well conserved (40–43%), consistent with their forming the core tetraspanin structure [37].
The cytoplasmic tails of TspanC8s are relatively divergent. The 25% and 27% sequence identities of the N- and
C-terminal tails, respectively (Figure 6), actually under-represent the true diversity, because the sequence
Table 1 Amino acid sequence identities for the human TspanC8s
Sequence analyses were performed using the Clustal Omega multiple sequence
alignment tool [57] and presented as percentage identity.
Tspan10 Tspan33 Tspan14 Tspan5 Tspan17
Tspan15 26.3 34.0 31.6 32.6 30.2
Tspan10 32.1 32.5 34.5 33.9
Tspan33 40.1 42.3 42.7
Tspan14 57.8 57.0
Tspan5 78.4
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alignment tool does not factor in the substantially different lengths of the TspanC8 tails (Figure 4). These are
unusually long in TspanC8s, averaging 29 and 36 amino acids for the N- and C-tail, respectively, and as long as
77 amino acids for the Tspan10 N-terminus and 74 amino acids for the Tspan17 C-terminus. This compares
with 10–15 amino acids for most other tetraspanins. The functions of the cytoplasmic regions of TspanC8s are
not known, although Tspan10 (previously named oculospanin) and Tspan15 (previously named NET-7) have
putative dileucine-based and tyrosine-based intracellular sorting motifs, respectively [58]. Thus, cytoplasmic
regions could engage with intracellular trafﬁcking proteins and be partly responsible for the distinct TspanC8 sub-
cellular localisations which have been reported [39,43]. As a precedent for such a mechanism, the C-terminus of
tetraspanin CD63 binds to the PDZ domain-containing protein syntenin-1, which regulates the constitutive
internalisation of the tetraspanin [59]. ADAM10 trafﬁcking to neuronal synapses is regulated by interaction with
the PDZ domain-containing synapse-associated protein-97 (SAP97) [60], but it is unclear whether TspanC8s
could also interact with SAP97. ADAM10 trafﬁcking to the cell surface is also regulated by Rab14a and its
guanine nucleotide exchange factor FAM116A [61], but no direct association between ADAM10 and Rab14a/
FAM116a has been reported. Thus, it is possible that the cytoplasmic tails of TspanC8 tetraspanins may play a
role in the trafﬁcking of ADAM10, by interacting with Rab GTPases and/or their effectors.
Future directions
Cell biology experiments will aim to determine the molecular mechanisms by which TspanC8s localise
ADAM10 to distinct substrates. Biophysical methods will investigate whether ADAM10 adopts different con-
formations in complex with different TspanC8s. It will also be important to generate antibodies and small
molecules to modulate speciﬁc TspanC8/ADAM10 complexes with the ultimate goal of disease treatment.
Finally, since it is well established that cholesterol depletion activates ADAM10 [62–64], could this be due to a
conformational change in TspanC8s, which serves as a trigger for ADAM10 activation?
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